Maple Grove, MN – According to filings with the U.S. Securities and Exchange Commission, StemoniX is raising $10,890,965.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Ping Yeh played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About StemoniX

At StemoniX our mission is to accelerate the discovery of new medicines with physiologically-relevant, structured human cells that improve cell-based assay outcomes. We develop and scalably manufacture human induced pluripotent stem (iPS) cell-derived cardiac and neural platforms for drug discovery and development. Predictive, accurate, and consistent, our human models enable scientists to quickly and economically conduct research with improved outcomes in a simplified workflow. We also collaborate with drug discovery organizations to test their compounds with our in-house screening capabilities, create new cell-based models, and operationalize their human iPS cells at large scale for high throughput screening.

To learn more about StemoniX, visit http://stemonix.com/

Contact:
Ping Yeh, Chief Executive Officer
612-802-9299
ping.yeh@stemonix.com
https://www.linkedin.com/in/ping-yeh-ms-mba-pmp-pgmp-7652795/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved